

# HPV Prevention and Control Board

**Alex Vorsters**

**Dur-e-Nayab Waheed**



[www.hpvboard.org](http://www.hpvboard.org)

# Aims & Objectives

## Aim

- To contribute to the prevention and control of HPV and HPV related diseases
- To generate, multiply and disseminate relevant information on HPV to a broad array of stakeholders

## Objectives

- Provide evidence-based guidance on key technical and strategic issues by organizing two meetings per year i.e., 1) technical meeting and 2) country meeting
- Monitor the progress of HPV control programs at the country and regional levels.



# A multi-disciplinary Board formed by prominent experts

- Act in their personal capacity
- Are often affiliated with stakeholding partners
- This provides open and honest discussions
- Advisors and speakers at HPV Prevention & Control Board meetings are not paid
- No formal organisation with president, vice-president i.e., minimal bureaucratic structure

## Advisors

- **Dr. Alex Vorsters**
  - *University of Antwerp, Belgium*
- **Prof. Dr. Anna Giuliano**
  - *Moffitt Cancer Center, USA*
- **Prof. Dr. Eduardo Franco**
  - *McGill University, Canada*
- **Dr. Heidi Larson**
  - *London School of Hygiene and Tropical Medicine, UK*
- **Dr. Kate Cuschieri**
  - *Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, Scotland, UK*
- **Prof. Mamadou Diop**
  - *Joliot Curie Cancer institute of Dakar, Senegal*
- **Dr. Marc Arbyn**
  - *Scientific Institute of Public Health, Belgium*
- **Dr. Mark Kane**
  - *Consultant USA*
- **Prof. Dr. Mario Poljak**
  - *Institute of Microbiology and Immunology, clinical Microbiology, Slovenia*
- **Prof. Dr. Margaret Stanley**
  - *University of Cambridge, UK*



# A multi-disciplinary Board formed by prominent experts

## Advisors

- **Prof. dr. Mira Kojouharova**
  - *National Centre of Infectious and Parasitic Diseases (NCIPD), Bulgaria*
- **Prof. Dr. Narendra Kumar Arora**
  - *The INCLEN Trust International*
- **Prof. dr. Nubia Muñoz**
  - *The National Cancer Institute of Colombia*
- **Prof. Dr. Pierre Van Damme**
  - *University of Antwerp, Belgium*
- **Prof. Dr. Paolo Bonanni**
  - *University of Florence, Italy*
- **Dr. Silvia de Sanjosé**
  - *Catalan Institute of Oncology (ICO), Spain*
- **Dr. Sharon Hanley**
  - *Hokkaido University, Japan*

- **Prof. Dr. Susanne Krüger Kjaer**
  - *University of Copenhagen, Denmark*
- **Prof. Suzanne Garland**
  - *University of Melbourne, Australia*
- **Dr. Xavier Bosch**
  - *Catalan Institute of Oncology (ICO), Spain*

## Observers

- Dr. Iacobo Baussano, IACR
- Dr. Nedret Emiroglu, WHO Euro
- Mr. Tarik Derrough, ECDC
- Dr. Liudmila Mosina , WHO Euro
- Dr. Lauri Markowitz, CDC, USA





# Viral Hepatitis Prevention Board

[VHPB News](#) | [About us](#) | [Meetings](#) | [Publications](#) | [Resources](#) | [Links](#) | [Contact us](#)

search

## VHPB Meetings

Pre-meeting documents

Presentations

Meeting output

Prevention and control of viral hepatitis in Spain: Lessons learnt and the way forward

▶ 2006 November | Madrid, Spain

Prevention and control of perinatal hepatitis B virus (HBV) transmission in the WHO European Region

▶ 2006 March | Istanbul, Turkey

Can the United Kingdom control viral hepatitis?

▶ 2005 November | Edinburgh, United Kingdom

Hepatitis B, hepatitis C, and other blood-borne infections in healthcare workers

▶ 2005 March | Rome, Italy

Prevention and control of viral hepatitis in France: Lessons learnt and the way forward

▶ 2004 November | Veyrier-Du-Lac, France

Strengthening immunisation systems and introduction of hepatitis B vaccine in Central and Eastern Europe and the Newly Independent States

▶ 2004 May | Kyiv, Ukraine

# HPV Board Secretariat

- Personnel involved\*:

- Alex Vorsters
- Brenda Janssens
- Dur-e-Nayab Waheed
- Xenia Mikulla
- Greet Hendrickx
- Sara Valckx



- Executive Secretary: Pierre Van Damme




- Located within the facilities of the Centre for the Evaluation of Vaccination (CEV), University of Antwerp

\*: Total involvement of 2.0 FTE, all member have other tasks at the department.



# Secretariat Activities

- Preparation and organisation of meetings
  - Publications
  - Media activities
  - Website: [www.hpvboard.org](http://www.hpvboard.org)
  - Participation in third party meetings
  - All financial issues are done by the rules of the University of Antwerp
-  Permanent intensive communication between HPV board members and secretariat



# HPV Prevention and Control Board Website

## HPV Prevention and Control Board



The HPV Prevention and Control Board was created in December 2015 with the aim to share relevant information on HPV with a broad array of stakeholders.

The HPV Prevention and Control Board is composed of a group of experts, who set the strategy and define the actions.

The HPV Board has a permanent executive secretariat, located at the [Vaccine & Infectious Disease Institute \(VAXINFECTIO\)](#) of the University of Antwerp.





# HPV Prevention and Control Board Kick-Off meeting 1-2 December 2015



**Barriers in HPV Vaccination & cervical screening programmes.  
27-28 June 2016 Meeting Antwerp**



**Country meeting: 'Prevention and control of HPV and HPV related cancers in Denmark: lessons learnt and the way forward'  
17-18 November 2016, Copenhagen, Denmark**



**Technical meeting: Symposium: Building Trust, Managing Risk:  
Vaccine Confidence and Human Papillomavirus Vaccination,  
7-8 June 2017, London, UK**



# Country meeting: 'Prevention and control of HPV and HPV related cancers in Ireland and the UK: lessons learnt and the way forward'

30<sup>th</sup> November – 1 December 2017, Dublin, Ireland.



As the meeting was held in Dublin, we had the honour to have Mr Simon Harris, Minister of Health of Ireland, open the meeting. In his [speech](#), he reiterated his full support to the HPV vaccination programme in Ireland and emphasized the role of qualified medical professionals



# The role of HCP in HPV vaccination and screening programme implementation - Prevention and control of HPV and HPV related cancers in Romania, 15 & 16 May 2018

## Short Videos



Benefits and Safety of HPV Vaccination  
- Dr. Xavier Bosch



USA - Helping healthcare providers  
improve HPV communication - Dr. Noel  
Brewer



# HPV Vaccination of Adults : Impact, Opportunities and Challenges. 14 & 15 Nov 2019

## Videos



Potential Benefits of HPV Vaccine in sexually active women: delivering the promise - John Schiller



Towards cervical cancer elimination: the context of HPV Vaccination - Paul Bloem



# Country Meeting in France - 2021



# Publications in Scientific Journals

## Papillomavirus Research:


Manuscript on ‘Overcoming barriers in HPV vaccination and screening programs’

## Vaccine:

HPV Immunization programs: Ensuring their sustainability and resilience.

## Papilloma Virus Research:

The Role of healthcare providers in HPV Vaccination Programs- A meeting report



### Overcoming barriers in HPV vaccination and screening programs

Alex Vorsters <sup>a</sup> ✉, Marc Arbyn <sup>b</sup>, Marc Baay <sup>c</sup>, Xavier Bosch <sup>d</sup>, Silvia de Sanjosé <sup>d, e</sup>, Sharon Hanley <sup>f</sup>, Emilie Karafillakis <sup>g</sup>, Pier Luigi Lopalco <sup>h</sup>, Kevin G. Pollock <sup>i</sup>, Joanne Yarwood <sup>j</sup>, Pierre Van Damme <sup>a</sup>

Vaccine 36 (2018) 5219–5221



Commentary

HPV immunization programs: Ensuring their sustainability and resilience

Alex Vorsters <sup>\*</sup>, Pierre Van Damme

*Centre for the Evaluation of Vaccination, University of Antwerp, Belgium*



The role of healthcare providers in HPV vaccination programs – A meeting report



# Publications in Scientific Journals

## BMC Proceedings:

Prevention and control of HPV infection and HPV-related cancers in Colombia.

Vorsters et al. *BMC Proceedings* 2020, **14**(Suppl 9):8  
<https://doi.org/10.1186/s12919-020-00192-2>

BMC Proceedings

MEETING REPORT

Open Access

## Prevention and control of HPV infection and HPV-related cancers in Colombia- a meeting report



Alex Vorsters<sup>1\*</sup>, Francisc Xavier Bosch<sup>2,3</sup>, Paolo Bonanni<sup>4</sup>, Eduardo L. Franco<sup>5</sup>, Marc Baay<sup>6</sup>, Clarissa Simas<sup>7</sup>, Dur-e-Nayab Waheed<sup>1</sup>, Carlos Castro<sup>8</sup>, Raul Murillo<sup>9</sup>, Lina Trujillo<sup>10</sup>, Carolina Wiesner<sup>10</sup> and Nubia Muñoz<sup>10</sup>

From Prevention and control of HPV and HPV related cancers in Colombia: Lessons learnt and the way forward Bogota, Colombia. 15-16 November 2018

## Acta Dermatovenerologica

Impact of the COVID-19 pandemic on human papillomavirus-based testing services to support cervical cancer screening

Acta Dermatovenerol APA

Acta Dermatovenerologica  
Alpina, Pannonica et Adriatica

2021;30:21-26  
doi: 10.15570/actaapa.2021.5

## Impact of the COVID-19 pandemic on human papillomavirus-based testing services to support cervical cancer screening

Mario Poljak<sup>1</sup>, Kate Cuschieri<sup>2</sup>, Dur-e-Nayab Waheed<sup>3</sup>, Marc Baay<sup>4</sup>, Alex Vorsters<sup>3,5</sup>

<sup>1</sup>Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. <sup>2</sup>Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, NHS Lothian Scotland, Edinburgh, United Kingdom. <sup>3</sup>Centre for Evaluation of Vaccination, Vaccine and Infectious Diseases Institute, University of Antwerp, Wilrijk, Belgium. <sup>4</sup>Pg5 Epidemiology & Pharmacovigilance, Leuven, Belgium.





# Publications in Scientific Journals

Preventive Medicine 156 (2022) 106960



ELSEVIER

Contents lists available at [ScienceDirect](https://www.sciencedirect.com)

Preventive Medicine

journal homepage: [www.elsevier.com/locate/ypmed](http://www.elsevier.com/locate/ypmed)



## HPV prevention and control – The way forward

Alex Vorsters<sup>a,\*</sup>, F. Xavier Bosch<sup>b,f</sup>, Mario Poljak<sup>c</sup>, Dur-e-Nayab Waheed<sup>a</sup>, Margaret Stanley<sup>d</sup>, Suzanne M. Garland<sup>e</sup>, on behalf of the HPV Prevention and Control Board and the International Papillomavirus Society (IPVS)

<sup>a</sup> Center for the Evaluation of Vaccination & HPV Prevention and Control Board, University of Antwerp, Antwerp, Belgium

<sup>b</sup> Cancer Epidemiology Research Program, IDIBELL, Catalan Institute of Oncology, L'Hospitalet De Llobregat, Barcelona, Spain

<sup>c</sup> Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

<sup>d</sup> Department of Pathology, University of Cambridge, United Kingdom

<sup>e</sup> Department of Obstetrics and Gynaecology, University of Melbourne, Centre Women's Infectious Diseases Research, Royal Women's Hospital, Murdoch Children's Research Institute, Australia

<sup>f</sup> Open University of Catalonia, Barcelona, Spain

### ARTICLE INFO

#### Keywords

HPV  
Prevention and control  
Cervical cancer  
COVID-19 pandemic  
Elimination  
Screening  
Vaccination

### ABSTRACT

The global confrontation with COVID-19 has not only diverted current healthcare resources to deal with the infection but has also resulted in increased resources in the areas of testing and screening, as well as educating most of the global public of the benefits of vaccination. When the COVID-19 pandemic eventually recedes, the opportunity must not be missed to ensure that these newly created resources are maintained and redeployed for use in testing and immunisation against other vaccine-preventable infectious diseases. A notable example is infection by human papillomavirus (HPV), the commonest sexually transmitted human virus and the leading cause of a variety of cancers in both men and women, such as cervical, head and neck, anal, vaginal, vulvar and



# Background Document

Technical Meeting

HPV prevention and control in People Living With HIV

Benefits and Challenges of Immunobridging trials

DNA Methylation as a Triage Tool for Cervical Cancer  
Screening

2 - 3 June, 2022  
Antwerp, Belgium

BACKGROUND DOCUMENT

DRAFT

Document will be finalized after the meeting

*Dur-e-Nayab Waheed and Alex Vorsters*

*HPV Prevention & Control Board*

Executive Secretariat, Vaccine and Infectious disease Institute, University of Antwerp, Campus Drie Eiken,  
Universiteitsplein 1, 2610 Antwerp, Belgium.

## Contents

<i>Part 1: Ovid/Medline Search by Topic .....</i>	<i>2</i>
<i>HPV prevention and control in HIV positives .....</i>	<i>3</i>
<i>Immunobridging .....</i>	<i>15</i>
<i>HPV and DNA methylation .....</i>	<i>21</i>
<i>Part 2: Bibliography of Speakers .....</i>	<i>34</i>
<i>Aimee R. Kreimer, Senior Investigator, Infections &amp; Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, NCI .....</i>	<i>35</i>
<i>Carina Eklund, Center for cervical cancer prevention, Karolinska Institute, Stockholm, Sweden ....</i>	<i>35</i>
<i>Chris JLM. Meijer, Professor of Pathology, Department of Pathology, Amsterdam University Medical Center (UMC), Location VUMC, Netherlands.....</i>	<i>35</i>
<i>Deborah Watson-Jones, Professor of Clinical Epidemiology and International Health, Mwanza Intervention Trials Unit (MITU)/ National Mwanza, Tanzania, National Institute for Medical Research (NIMR) and the London School of Hygiene and Tropical Medicine (LSHTM).....</i>	<i>36</i>
<i>Daniëlle Heideman, Clinical Scientist in Molecular Pathology and Associate Professor, Department Pathology, Amsterdam UMC Department of Pathology, Amsterdam The Netherlands.....</i>	<i>37</i>
<i>Filipe Colaco Mariz, PhD/Research Assistant, German Cancer Research Center (DKFZ).....</i>	<i>38</i>
<i>Gary Clifford, Deputy Head. Branch of Early Detection, Prevention and Infections. International Agency for Research on Cancer (IARC), Lyon, France .....</i>	<i>38</i>
<i>Helen Kelly, Epidemiologist, Associate Professor, London School of Hygiene and Tropical Medicine, National Cancer Institute .....</i>	<i>39</i>
<i>Iacopo Baussano, Scientist, Team Leader of the Public Health Decision Modelling Team, International Agency for Research on Cancer.....</i>	<i>40</i>
<i>Jack Cuzick, Head of Cancer Prevention Section, Wolfson Institute of Public Health .....</i>	<i>40</i>
<i>Joel Palefsky, Professor of Medicine, University of California, San Francisco, USA.....</i>	<i>41</i>
<i>Johannes Berkhof, Professor, Amsterdam UMC, Netherlands .....</i>	<i>41</i>
<i>Karolina Louvanto, MD, PhD, Tenure track Professor and Deputy Chief of Obstetrics and Gynecology, Tampere University and Tampere University Hospital, Finland .....</i>	<i>42</i>
<i>Mariam El-Zein, Associate Director for Research, Division of Cancer Epidemiology, McGill University .....</i>	<i>43</i>
<i>Paul Bloem, Technical Officer, HPV vaccine impact lead, Department of Immunization, Vaccines and Biologicals (IVB), WHO, Geneva .....</i>	<i>44</i>
<i>PART 3: HPV PREVENTION AND CONTROL BOARD OUTPUT .....</i>	<i>46</i>

**Focused Topic Technical Meeting:**

HPV prevention and control in People Living With HIV

Benefits and Challenges of Immunobridging trials

DNA Methylation as a Triage Tool for Cervical Cancer Screening

**2 - 3 June 2022**

**Antwerp, Belgium**

# Meeting objectives (1):

- **HPV prevention and control in People Living With HIV**
  - Discuss and review the HPV vaccine schedule for People Living With HIV
  - Discuss HPV screening of People Living With HIV
  - Discuss and review the management of women with HIV who are HPV positives
- **Benefits and Challenges of Immunobridging trials**
  - Discuss availability and use of different HPV immunoassays
  - Discuss challenges and prospects of immunobridging trials for evaluating current and future HPV vaccines



# Meeting objectives (2):

- **DNA Methylation as a triage tool for cervical cancer screening**
  - Provide an overview of the use of DNA methylation in the oncology field
  - Provide an overview of different DNA methylation assays and methods
  - Discuss the use of DNA methylation as a novel biomarker for triage of human papillomavirus (HPV) positive women at screening



# Practical Announcements

**Please note that it's a hybrid meeting – we will appreciate that online and physical participants respect the time.**

## **Physical Participants**

- There is one mic on each table. Please use the mic on your table to ask the question. It will help the online participants to follow the questions and discussion in the meeting room

## **Online Participants**

- Please switch on your video while introducing yourself and every time you speak
- Keep yourself on mute when not speaking
- Please make use of the chat function to ask any burning questions/comments or observations.

## **Physical and Online Participants**

- We will open the breakout rooms closer to the session time and ask you to choose one based on your expertise and interest. We will appreciate that you keep your video on during the breakout group session, if your internet connection is stable.
- Breakout group chairs: please ensure that online and physical participants get opportunity to share their experience



# Vaccinopolis Visit

